{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:53:15Z","timestamp":1790679195278,"version":"4.1.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1681\/asn.2014121226","type":"journal-article","created":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T20:00:42Z","timestamp":1430510442000},"page":"256-264","source":"Crossref","is-referenced-by-count":122,"title":["Serum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease"],"prefix":"10.1681","volume":"27","author":[{"given":"Malte","family":"Lenders","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Stypmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Duning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan-Martin","family":"Brand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Brand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-28-20230208","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","article-title":"Fabry\u2019s disease.","volume":"372","author":"Zarate","year":"2008","journal-title":"Lancet"},{"key":"R2-28-20230208","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A\u2014replacement therapy in Fabry\u2019s disease.","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J Med"},{"key":"R3-28-20230208","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial.","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"R4-28-20230208","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta.","volume":"66","author":"Linthorst","year":"2004","journal-title":"Kidney Int"},{"key":"R5-28-20230208","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ymgme.2008.10.004","article-title":"A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease.","volume":"96","author":"B\u00e9nichou","year":"2009","journal-title":"Mol Genet Metab"},{"key":"R6-28-20230208","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymgme.2008.10.013","article-title":"Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome?","volume":"96","author":"Hollak","year":"2009","journal-title":"Mol Genet Metab"},{"key":"R7-28-20230208","doi-asserted-by":"crossref","first-page":"e47805","DOI":"10.1371\/journal.pone.0047805","article-title":"Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome.","volume":"7","author":"Rombach","year":"2012","journal-title":"PLoS ONE"},{"key":"R8-28-20230208","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.echo.2005.10.005","article-title":"Recommendations for chamber quantification: a report from the American Society of Echocardiography\u2019s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology.","volume":"18","author":"Lang","year":"2005","journal-title":"J Am Soc Echocardiogr"},{"key":"R10-28-20230208","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ymgme.2011.12.006","article-title":"Anti-\u03b1-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry Registry.","volume":"105","author":"Wilcox","year":"2012","journal-title":"Mol Genet Metab"},{"key":"R11-28-20230208","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2012030316","article-title":"Agalsidase benefits renal histology in young patients with Fabry disease.","volume":"24","author":"T\u00f8ndel","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"R12-28-20230208","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1681\/ASN.2013121322","article-title":"Fabry disease: dose matters.","volume":"25","author":"Warnock","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"R13-28-20230208","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1681\/ASN.2013060585","article-title":"Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch.","volume":"25","author":"Weidemann","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"R14-28-20230208","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/S0149-2918(08)80041-0","article-title":"The immunogenicity of therapeutic proteins and the Fabry antibody standardization initiative.","volume":"30 Suppl B","author":"Schellekens","year":"2008","journal-title":"Clin Ther"},{"key":"R15-28-20230208","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1542\/peds.100.6.e11","article-title":"Management of neutralizing antibody to Ceredase in a patient with type 3 Gaucher disease.","volume":"100","author":"Brady","year":"1997","journal-title":"Pediatrics"},{"key":"R16-28-20230208","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1182\/blood.V93.6.2081.406k07_2081_2088","article-title":"Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration.","volume":"93","author":"Rosenberg","year":"1999","journal-title":"Blood"},{"key":"R17-28-20230208","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/8904_2011_34","article-title":"Immune modulation therapy in a CRIM-positive and IgG antibody-positive infant with Pompe disease treated with alglucosidase alpha: A case report.","volume":"2","author":"Markic","year":"2012","journal-title":"JIMD Rep"},{"key":"R18-28-20230208","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1750-1172-8-51","article-title":"Mucopolysaccharidosis type VI phenotypes-genotypes and antibody response to galsulfase.","volume":"8","author":"Brands","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"R19-28-20230208","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.jacc.2010.11.002","article-title":"ACCF\/ASE\/AHA\/ASNC\/HFSA\/HRS\/SCAI\/SCCM\/SCCT\/SCMR 2011 Appropriate Use Criteria for Echocardiography. A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance Endorsed by the American College of Chest Physicians.","volume":"57","author":"Douglas","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"R20-28-20230208","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate.","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"R21-28-20230208","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C.","volume":"367","author":"Inker","year":"2012","journal-title":"N Engl J Med"},{"key":"R22-28-20230208","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1399-0004.2004.00219.x","article-title":"The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy.","volume":"65","author":"Whybra","year":"2004","journal-title":"Clin Genet"},{"key":"R23-28-20230208","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ymgme.2009.10.178","article-title":"A validated disease severity scoring system for Fabry disease.","volume":"99","author":"Giannini","year":"2010","journal-title":"Mol Genet Metab"},{"key":"R24-28-20230208","first-page":"157","article-title":"Fabry\u2019s disease: enzymatic diagnosis of hemizygotes and heterozygotes. Alpha-galactosidase activities in plasma, serum, urine, and leukocytes.","volume":"81","author":"Desnick","year":"1973","journal-title":"J Lab Clin Med"},{"key":"R25-28-20230208","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0009-8981(81)90384-3","article-title":"Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry\u2019s disease.","volume":"112","author":"Mayes","year":"1981","journal-title":"Clin Chim Acta"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001751-201601000-00028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:26:22Z","timestamp":1786130782000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001751-201601000-00028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2014121226","relation":{},"ISSN":["1046-6673"],"issn-type":[{"value":"1046-6673","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]}}}